New pill aims to calm Flare-Ups in ulcerative colitis
NCT ID NCT07535489
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill, IPG11406, in 144 adults with moderate to severe ulcerative colitis (UC), a chronic gut condition causing diarrhea and pain. The drug targets immune cells to reduce colon inflammation. Participants receive one of three doses or a placebo for 12 weeks to see if it safely induces remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Beijing, China